Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state
Open Access
- 1 March 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 23 (3), 135-141
- https://doi.org/10.1097/fpc.0b013e32835d9ab0
Abstract
Background Bupropion, an antidepressant and smoking cessation medication, is metabolized to hydroxybupropion (HB), an active metabolite, primarily by CYP2B6. Objectives To compare plasma concentrations of bupropion and metabolites at steady state in healthy volunteers with and without CYP2B6 genetic variants. Methods In a genotype-guided study of 42 healthy individuals, we measured the plasma and urine concentrations of bupropion and its metabolites, HB, threohydrobupropion, and erythrohydrobupropion after 7 days of sustained-release bupropion dosing. Results CYP2B6*6 and *18 gene variants were associated with ∼33% reduced concentrations of HB, with no effects on concentrations of bupropion or other metabolites. We could account for 50% of the variation in HB concentrations in a model including genotype and sex. Conclusion As HB is active and its steady-state concentrations are more than 10 times higher than bupropion, CYP2B6 variants are likely to affect pharmacological activity. Because of the large individual variation within the genotype group, the use of therapeutic drug monitoring for dose optimization may be necessary.Keywords
This publication has 32 references indexed in Scilit:
- CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native peoplePharmacogenetics and Genomics, 2012
- Polymorphic Variants of Cytochrome P450 2B6 (CYP2B6.4–CYP2B6.9) Exhibit Altered Rates of Metabolism for Bupropion and Efavirenz: A Charge-Reversal Mutation in the K139E Variant (CYP2B6.8) Impairs Formation of a Functional Cytochrome P450-Reductase ComplexJournal of Pharmacology and Experimental Therapeutics, 2011
- Effects of Hydroxymetabolites of Bupropion on Nicotine Dependence Behavior in MiceJournal of Pharmacology and Experimental Therapeutics, 2010
- Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolismXenobiotica, 2010
- Stereoselective Bupropion Hydroxylation as an In Vivo Phenotypic Probe for Cytochrome P4502B6 (CYP2B6) ActivityThe Journal of Clinical Pharmacology, 2008
- Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in LiverJournal of Pharmacology and Experimental Therapeutics, 2008
- Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissuesPharmacogenetics and Genomics, 2006
- Bupropion for major depressive disorder: Pharmacokinetic and formulation considerationsClinical Therapeutics, 2005
- Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship toCYP2B6Genotype and CAR (Constitutive Androstane Receptor) ExpressionJournal of Pharmacology and Experimental Therapeutics, 2003
- Pharmacokinetic Optimisation of Sustained-Release Bupropion for Smoking CessationDrugs, 2002